(Q42818861)

English

Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib

scientific article published on 25 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Toshio Matsumoto

14

object named as

Toshio Matsumoto

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

author name string

Shingen Nakamura

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Hirokazu Miki

2

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Shinsuke Kido

3

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Ayako Nakano

4

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Masahiro Hiasa

5

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Asuka Oda

6

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Hiroe Amou

7

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Keiichiro Watanabe

8

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Takeshi Harada

9

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Shiro Fujii

10

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Kyoko Takeuchi

11

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Kumiko Kagawa

12

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Shuji Ozaki

13

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Masahiro Abe

15

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

publication date

25 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

66-73

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

The IRE1α-XBP1 pathway is essential for osteoblast differentiation through promoting transcription of Osterix

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis and transcriptional activation for bone remodeling.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

From endoplasmic-reticulum stress to the inflammatory response

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Transcription factors controlling osteoblastogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

CCAAT/enhancer-binding protein beta promotes osteoblast differentiation by enhancing Runx2 activity with ATF4.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

CCAAT/enhancer-binding protein homologous protein (CHOP) regulates osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Osteoblastogenesis and tumor growth in myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1367-Z

21 January 2018

Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/23708974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/23708974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23708974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23708974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-013-1367-Z

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42818861&oldid=2258475807"